Innate Pharma S.A.
IPHA
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.78
Price-1.38%
-$0.02
1Y
Price
Market Cap
$149.543m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-7734.8%
EBITDA Margin-8951.8%
Net Profit Margin-3637.7%
Free Cash Flow MarginRevenue
$69.408m
+33.7%
1y CAGR+133.3%
3y CAGR+79.3%
5y CAGREarnings
-$57.041m
-653.5%
1y CAGR-188.3%
3y CAGR-139.3%
5y CAGREPS
-$0.71
-688.9%
1y CAGR-200.0%
3y CAGR-1975.0%
5y CAGRBook Value
$8.834m
$111.059m
Assets$102.225m
Liabilities$30.995m
DebtDebt to Assets
27.9%
-0.5x
Debt to EBITDAFree Cash Flow
-$40.199m
-15.1%
1y CAGR-7.1%
3y CAGR-4.0%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in EUR.No items found.
Press Releases
Statements and updates from the company